We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report)’s share price was down 4.6% on Thursday after UBS Group lowered their price target on the stock from $30.00 to $27.00. UBS Group ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported fourth-quarter earnings that beat analyst estimates, but its shares fell sharply as the company's 2025 outlook came in below ...